Colorectal carcinoma (CRC) · line 1 · Pembrolizumab monotherapy (MSI-H mCRC 1L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-PEMBROLIZUMAB-MSI-MONO`

ID	`IND-CRC-METASTATIC-1L-MSI-H-PEMBRO`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-KEYNOTE-177-ANDRE-2020` `SRC-NCCN-COLON-2025`

Notes

STUB — Phase GI-1. CI-PEMBROLIZUMAB-AUTOIMMUNE referenced but not yet authored; MSI test entities (TEST-MSI-PCR-OR-NGS, TEST-DMMR-IHC) also pending — engine validation will flag these as unresolved refs until authored.

Used By

Algorithms

ALGO-CRC-METASTATIC-1L - ALGO-CRC-METASTATIC-1L

Contraindications

CI-PEMBROLIZUMAB-AUTOIMMUNE - CI-PEMBROLIZUMAB-AUTOIMMUNE

Handbook Chapters

HB-CRC-METASTATIC-1L - Metastatic colorectal cancer: first-line biomarker reasoning

Handbook Questions

HQ-CRC-MET-1L-001 - HQ-CRC-MET-1L-001